CAR T Cell Therapy for Lymphoma, Leukemia, and Myeloma: Experts Answer Clinician Questions
Listen to Michael R. Bishop, MD; Daniel J. DeAngelo, MD, PhD; and Noopur Raje, MD, answer audience questions from a series of live CCO Webinars focused on current best practices and emerging applications with CAR T-cell therapy.
Decera Clinical Education Oncology Podcast · Michael R. Bishop MD, Daniel J. DeAngelo MD PhD, Noopur Raje MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Michael R. Bishop, MD; Daniel J. DeAngelo, MD, PhD; and Noopur Raje, MD, answer clinician questions on current best practices and emerging applications with CAR T-cell therapy, with topics including:
- Optimal use of approved CAR T-cell therapies for lymphoma and ALL
- Investigational CAR T-cell therapies for multiple myeloma
- Managing CAR T-cell therapy–related toxicities
Presenters:
Michael R. Bishop, MD
Professor of Medicine
Section of Hematology/Oncology
Director, Cellular Therapy Program
University of Chicago
Chicago, Illinois
Daniel J. DeAngelo, MD, PhD
Professor of Medicine
Department of Medicine
Harvard Medical School
Chief, Division of Leukemia
Department of Medical Oncology
Division of Hematologic Malignancies
Dana‐Farber Cancer Institute
Boston, Massachusetts
Noopur Raje, MD
Professor of Medicine
Harvard Medical School
Director
Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Boston, Massachusetts
Content based on an online CME program supported by educational grants from Celgene Corporation and Legend Biotech USA Inc.
Link to full program:
https://bit.ly/3iyt5zQ
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.